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Abstract:This report provides an outline of a program for the discovery of newpublic health insecticides formalaria
vector control. The status of malaria vector control is first reviewed in terms of the chemical, physical chemical,
and biochemical properties of the current WHOPES-recommended and approved vector control agents. This
review provides a basis for a discussion on the critical need for discovery and development of multiple new
chemical malaria vector control agents with novel and diverse modes of action. The Innovative Vector Control
Consortium (IVCC) New Active Ingredient Target Product Profile (TPP) describes the essential attributes for
a successful new malaria vector control agent and then serves as the basis for development of a discovery
cascade. The cascade addresses these attributes experimentally at each stage of the discovery process – from
design and assembly of an appropriate collection of chemicals for screening, through development of testing
protocols to sort candidates, and into the detailed profiling of advanced pre-development candidates against TPP
requirements. In addition, this program defines a staged development system to provide intermediate guidance
to the insecticide explorer regarding the progress of their discovery program against the ultimate product goal.
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Introduction
Malaria is a debilitating and life-threat-
ening disease that seriously affects more
than 200 million people each year. The dis-
ease is caused by any one of five species of
Plasmodium parasites, which are transmit-
ted to humans through bites from female
Anopheles mosquitoes. The World Health
Organisation (WHO) provides an annual
‘World Malaria Report’
[1]
and a ‘Malaria
Fact Sheet’
[2]
which detail the global im-
pact of malaria upon human health and
provides information on the causes, treat-
ments, and control issues associated with
the disease (also see the ‘Global Technical
Strategy for Malaria 2016-2030’).
[3]
The
most recent reports include some alarming
statistics; for example, approximately 3.2
billion people (half of the world’s popu-
lation) residing in 97 countries are at risk
of developing malaria; in 2015 there were
over 438,000 deaths attributed to malaria,
with 90% of these occurring in sub-Saha-
ran Africa; the majority of deaths (70%)
are children under the age of 5 with one
child dying each minute from malaria in
Africa.
Although these statistics make grim
reading, enormous progress has been made
over the past century in reducing the dev-
astating effects caused by malaria. Malaria
eradication efforts in the 1900s eliminated
the disease from theUnitedStates aswell as
most of Europe, LatinAmerica and parts of
Asia. More recently theWHO reports that,
since 2000, “malaria death rates among
populations at risk fell by 60% globally
among all age groups, and by 65% among
children under 5”.
[2]
For all its dire conse-
quences, malaria is an entirely preventable
disease. Key components for controlling
malaria include prevention of transmission
through vector control, and prompt treat-
ment with combination drug therapies.
Twomethods have been shown to be highly
effective for control of the malaria vector:
indoor residual spraying (IRS) with insec-
ticides and the use of insecticide-treated
nets (ITN), in particular long-lasting in-
secticide-treated nets (LLIN).
[1,4,5]
When
properly deployed, these methods provide
individual protection from mosquitoes and
proven community-wide protection from
malaria transmission as a result of the sup-
pression of the number of parasite-infect-
ed insects.
[1]
A recent report estimates that,
between 2000–2015, 663 million cases of
malaria have been averted through malaria
disease control efforts. The vast majority
of these avoided cases were as a result of
the use of vector control methodologies –
an impressive 68% from use of ITN and
10% from IRS.
[5]
The ITN and IRS vector control meth-
odologies are ultimately dependent upon
the availability of a varied group of effec-
tive insecticide tools. Ideally, there would
be a selection of chemicals to choose from,
each of which would belong to a different
class of chemistry and function through
a unique mechanism of action at the bio-
molecular level within the mosquito. But
the current situation for chemical malaria
vector control is far from ideal. Currently,
thirteen insecticides are recommended
for IRS use for malaria vector control by
the World Health Organisation Pesticide
Evaluation Scheme (WHOPES).
[6]
But
these thirteen insecticides belong to only
four unique chemical classes, organochlo-
rines, organophosphates, carbamates, and
pyrethroids (Fig. 1), and function through
only two distinct mechanisms of action:
inhibition of acetylcholinesterase (organ-
ophosphates, carbamates) and disruption
of voltage-gated sodium channels (DDT,
pyrethroids).
[7]
The situation is even more
critical for ITN uses: there are only six
WHOPES-recommended insecticides for
ITN, all of which are members of a single
class of chemistry (pyrethroids) and there-
fore share a common target site of action.
[8]
To emphasise further the issue of avail-
able chemical tools, no new WHOPES-
recommended insecticide has been devel-
oped for use in public health for malaria
vector control in over 30 years.
Unfortunately, the lack of chemical di-
versity within the approved list of malaria
vector control agents results in an ideal
situation for development of insecticide
resistance in mosquitoes. Continual use of
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of-action for vector control. The availabili-
ty of such novelmaterials is deemed critical
for the prevention of wide-spread insecti-
cide resistance, particularly in ITN uses.
[9]
To help guide and direct this discovery and
development effort, the IVCC has prepared
a detailed set of specifications, known as
the New Active Ingredient Target Product
Profile (TPP),
[16,17]
for new chemical en-
tities intended for use as vector control
agents in either IRS or ITN. The TPP de-
tails the necessary features of a new vector
control insecticide, including its expected
performance characteristics (e.g. potency,
spectrum, speed of action), durability (re-
siduality on multiple surfaces), human and
environmental safety profile, acceptability
to the purchaser (cost-effectiveness) and
the end user.
In this report we provide an outline of
a program for the discovery of new pub-
lic health insecticides for malaria vector
control. The IVCC New Active Ingredient
TPP serves as the basis for development
of a discovery cascade and describes the
essential attributes for a successful new
malaria vector control agent. The cascade
addresses these attributes experimentally
at each stage of the discovery process –
from design and assembly of a collection
of chemicals for screening, through de-
velopment of testing protocols to sort and
rank candidates, into the detailed profil-
ing of advanced development candidates
against TPP requirements. In addition,
this program defines a staged development
system to provide intermediate guidance to
the insecticide explorer regarding the pro-
gress of their discovery program towards
the ultimate product goal.
Discovery Approaches
Since its inception, the pesticide in-
dustry has made successful use of in vivo
assays as the primary tool for discovery
of bioactivity and identification of ‘lead’
classes of chemistry. The long-time strate-
gy of the industry has been to conduct the
primary bioactivity screen directly against
the actual target organism, or a closely-re-
lated surrogate when the target is unavail-
able.
[18]
To understand the rationale for this
reliance on the in vivo approach, it is in-
structive to consider the discovery models
used by both the agricultural and pharma-
ceutical industries.
First, appropriate in vivomodels of hu-
man diseases are rarely available in a sim-
ple, inexpensive format that would allow
for direct screening and sorting of the tens
(or hundreds) of thousands of available
chemical inputs. Instead, potential target
sites (enzymes, receptors) believed to be
associated with a desired therapeutic out-
come are identified and significant effort
resistance within the wild Anopheles mos-
quito population and points to an expected
relationship between such resistance and
the effective level of control of the ITN.
[10]
TheBill andMelindaGates Foundation
have initiated an ambitious effort to erad-
icate malaria, a goal widely supported
within the international malaria communi-
ty and by WHO.
[11,12,13]
One consequence
of this initiative was the establishment of
the Innovative Vector Control Consortium
(IVCC), a public-private product develop-
ment partnership with a mission to “im-
prove the tools and technologies available
for malaria … vector control”.
[14,15]
A key
component of this mission is the discovery
and development of new malaria vector
control agents which would represent both
novel classes of chemistry and newmodes-
a single insecticide or class of insecticides
on a local mosquito population results
in selection for resistance via a genetic
change within the mosquito population
which can (a) render the insecticide less
effective at interaction with the biomolecu-
lar target site (target site resistance) or (b)
enhance the mosquito’s ability to metabol-
ically detoxify the insecticide (metabolic
resistance). Indeed, both types of resist-
ance, as well as combinations of the two,
have been widely documented against a
number of classes of insecticides, includ-
ing pyrethroids, organophosphates, car-
bamates, DDT and dieldrin, within wild
mosquito populations.
[4,9]
Furthermore,
a recent review and meta-analysis on the
use of pyrethroids in ITN documents the
presence of both target site and metabolic
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Fig. 1. WHOPES approved chemicals for malaria vector control.
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against indoor-biting mosquitoes, i.e. once
they have entered dwellings. While there
is the potential, and need, for novel tech-
niques to address outdoor biting mosqui-
toes, these may well utilise products devel-
oped for either ITN or IRS. An alternative
strategy for malaria vector control is the
use of toxic baits, such as attractive toxic
sugar baits (ATSB); these consist of a mos-
quito attractant combined with an appro-
priate, orally-active insecticide.
[20]
In this
case the toxicant can probably be based on
one of the many existing classes of stom-
ach-acting insecticides that are commonly
used for control of agronomically impor-
tant insects. This paper concentrates solely
on discovery of novel chemistry for ITN
and IRS use.
The ITN/IRS New Active Ingredient
Target Product Profile
[16]
provides defini-
tions for the EssentialAttributes (extracted
in a simple format in Table 1) needed in a
successful new product; all these proper-
ties must be met in order for a candidate to
advance into development. These Essential
Attributes therefore provide direct guid-
ance for the types of properties that must
be considered and evaluated during the
discovery process and for the design of the
screening cascade itself. Furthermore, the
TPP provides the context for a staging sys-
tem (Active, Hit, Lead) with well-defined
gates that allow a measure of progress
against the TPP at intermediate stages of
the discovery effort. The combination of
these Essential Attributes and the stag-
ing system can then be used to develop
a screening cascade for insecticide can-
didates (Fig. 2). The balance of this dis-
ing a measure of intrinsic activity and an
indication of potential for redistribution.
In contrast to the pharmaceutical industry
discovery model, ‘actives’ from these sim-
plified in vivo assays are relatively rare, but
those identified are sure to be addressing
a ‘validated’ (i.e. potentially lethal) target,
and have at least some molecular proper-
ties consistent with those required for ther-
apeutic control. Finally, it is worth noting
that assaying directly against the therapeu-
tic outcome maximises the opportunity for
serendipitous discovery.
Binding assays do nonetheless serve
important roles in the pesticide discovery
process. Such assays are valuable in the
lead optimisation process where an under-
standing of the intrinsic activity of a chem-
ical can play a critical role in structure-ac-
tivity relationship (SAR) development of a
lead series and in the identification of the
factors limiting expression of bioactivity
against the target organism. In addition, a
high-throughput in vitro assay can serve
as an initial sorting tool for selection of
chemicals for inclusion in a primary in
vivo assay.
Discovery Cascade
Malaria vector control insecticides tar-
geting adult mosquitoes are generally uti-
lised either in the form of insecticide treat-
ed nets (ITN) or as indoor residual sprays
(IRS). The latter are applied to the walls of
buildings, to leave a deposit of insecticide
that will kill insects resting on the treated
surface. These two techniques are targeted
is then made to establish the therapeutic
validity of these targets. An appropriate
in vitro binding assay is developed for the
target, typically in high throughput format,
and a screening set is designed and assem-
bled to find and sort potential leads. The
most promising leads from this assay are
then optimised for binding activity against
the target protein and the best (most ac-
tive and most “drug-like”) candidate(s)
ultimately tested in an in vivo system. The
main limitation of this strategy is that these
simple target-based assays have not prov-
en to be reliable predictors of activity on
the whole organism, since – at least for a
novel target – the importance of the target
to the disease (‘target validation’) can be
uncertain, and furthermore the primary
assays do not take into account additional
attributes, beyond intrinsic activity, which
are essential for whole organism activity
(e.g. oral availability, metabolic potential,
ability to cross membranes and distribute
within the organism). While this is a very
simplified analysis of an enormously more
complex process, identification of the fac-
tors that can limit therapeutic potential
may be uncovered only late in the discov-
ery process and only following extensive
and expensive activity optimisation efforts.
The challenge of translating in vitro
activity to in vivo is magnified in pesticide
discovery, where many additional compli-
cating factors exist. Among the more sig-
nificant of these are delivery mechanism
challenges, host/pest interactions, envi-
ronmental influences (UV degradation,
exposure to elements, e.g. air oxidation),
and surface interactions (soil, plant, insec-
ticide-treated net, wall). But ‘phenotypic’
screening directly against a target organ-
ism, for example an aphid on a plant or
an insect larva eating an artificial diet, in
a laboratory or greenhouse environment,
poses its own set of issues. Such a system
requires a significant quantity of often pre-
cious screening chemicals, is labour inten-
sive, and is difficult to miniaturise or scale
to the vast numbers of screening candidates
often available or required to develop suffi-
cient numbers of quality leads. Thus most
primary pesticide discovery is now con-
ducted via low-barrier, high-throughput in
vivo assays, using target pests or indicator
organisms as models for the actual target-
ed pests.
[19]
In the case of insecticide dis-
covery, this primary screen frequently in-
cludes measuring the kill of Aedes aegypti
larvae, which are bathed in an aqueous
solution of the chemical. A manageable
number of ‘actives’ are thus identified and
challenged against the target organisms
themselves (adult mosquitoes in this case)
in secondary assays. In this particular ex-
ample, continuous exposure of the insect to
the chemical minimises the effects of both
metabolism and uptake, while still provid-
Table 1. Essential attributes of a novel insecticide development candidate for malaria vector
control.
Activity topically active (lethal) against adult mosquitoes
Speed of Effect lethality within 72 hours of a 30-minute exposure
Potency at least equivalent to that of permethrin
Cross-resistance active against both target site and metabolically resistant
mosquito strains
Spectrum active against multiple mosquito species
(minimally Anopheles gambiae and Anopheles arabiensis)
ITN Fit demonstrated ability to formulate for use in bed-nets
· can be incorporated into or impregnated onto a polymer
matrix (ITN)
· predicted efficacy on nets, with routine washing, lasting
for 5 years (ITN)
IRS Fit demonstrated ability to formulate for use as a surface spray
· chemically stable (residual activity) for at least 6 months
on standard substrates – cement, wood, mud
Patent Status patentable or clear and exclusive freedom to operate
Human and Environ-
mental Safety
acceptable toxicological and eco-toxicological profiles
(defined in Target Product Profile)
Cost of Goods acceptable cost of goods; with reference to cost/time dura-
tion equal to or better than that for permethrin.
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probability-based rules for selection of
‘agrochemical-like’ screening inputs for
pesticide discovery (Table 3). An agro-
chemical probability predictor introduced
by Briggs
[25]
of Bayer (‘Briggs Rule of
3’ or ‘ground rules of three’) is included
alongside the Tice and Clarke-Delaney
guidelines, although details of Briggs’
analysis that led to these conclusions have
not been published. The selected proper-
ties differ within each approach, but they
all include molecular weight, a calculated
log P value and number of hydrogen-bond
donors in the molecule. Some other prop-
erties included in these guidelines, such as
melting point, water solubility and ∆ log P,
undoubtedly play important roles in the
inherent bioavailability of a chemical yet
are difficult to calculate and thus of limited
value as predictive tools.
Interestingly, despite the enormous
differences in activity barriers, applica-
tion methodologies, target organisms and
therapeutic outcomes between the various
classes of bioactive materials, there is a
similarity across the published guidelines
for most properties, even across therapeu-
tic areas. Perhaps this is not surprising as a
combination of these properties is required
to strike an optimal balance between pha-
macokinetics/biokinetics and biochemical
recognition. In other words, the guidelines
do indeed provide a good, if very general,
predictor of bioavailability. The striking
difference between the Lipinksi guidelines
and the agrochemical predictors is the rec-
ommended number of H-bond donors; the
guideline for maximum number of such
functionalities is 40–60% lower for agro-
chemicals than for pharmaceuticals.
Heading the list of Essential Attributes
in the ITN/IRS TPP (Table 1) is ‘contact
activity’ against an adult mosquito. Thus
the mosquito must pick the chemical up
from a surface (wall or bed net) and the
chemical must then cross the insect cuti-
cle, distribute within the insect to the target
tissue(s) and bind with a protein(s) at the
to select compounds for screening or com-
binatorial/parallel synthesis.
Similar molecular property analyses
have been conducted on pesticides, with
the ultimate goal of providing analogous
‘agrochemical-like’ rule-based guidance
for selection of screening inputs. The sum-
mary conclusions from two of these analy-
ses are compiled inTable 2. Themore com-
prehensive of these studies was reported by
Tice
[22]
of Rohm and Haas, who examined
the physical property and functional group
distribution of a collection of commercial
insecticides and herbicides. This analysis
is somewhat dated, and as a result does
not include some important newer class-
es of insecticides (e.g. diamides and most
neonicotinoids), but nonetheless does pro-
vide an extensive compilation of selected
physical properties of commercial insec-
ticides. A similar property analysis was
performed on the entire collection of com-
mercial pesticides by Clarke and Delaney
of Syngenta.
[23,24]
The latter report is inter-
esting to review since it includes a property
analysis not only of commercial pesticides,
but also of proprietary sets of screening in-
puts, in vivo actives, and pesticide leads.
In a manner analogous to the Lipinski
approach, these physical property anal-
yses were then used to develop sets of
cussion is directed towards the activities
and assays associated with each of these
discovery stages for a novel insecticide in-
tended for the control of mosquitoes acting
as vectors for human diseases.
Designing the Screening Collection
Physical Properties of Insecticides:
Bioavailability Predictors
The importance of the in vitro – in vivo
translation problem discussed above was
recognised by Lipinksi
[21]
in his seminal
paper on the physical properties of phar-
maceuticals. From an analysis of pharma-
ceutical databases, Lipinski introduced
the concept of ‘drug-like’ molecules and
developed what has become known as
the ‘Lipinski Rule of 5’ as a guideline for
selecting compounds for pharmaceutical
screens. The ultimate goal was to enrich
the screening set with molecules whose
‘drug-like’ properties would increase the
likelihood that lead materials would have
both high levels of intrinsic activity and be
bioavailable. The rules are particularly use-
ful as the properties identified by Lipinski
can be easily calculated with acceptable
levels of precision – for real or virtual mol-
ecules – on the often massive scale needed
Fig. 2. Screening cascade for a new insecticide.
Table 2. Selected physical properties of commercial insecticides (mean values unless noted)
Tice
[22]
Clarke-Delaney
[23]
all pesticides
Clarke-Delaney
[23]
insecticides
a
WHOPES recommended
insecticides
[6,8,26]
# of pesticides 243 1380 not specified 13
molecular weight 324 297 210–500 361
log P 3.5
b
3.0
c
0.9–6.6
c
4.9
H-bond donors
d
0.4 0.15
H-bond acidity
e
0.3 0–0.7
H-bond acceptors
f
4.1 3.5
H-bond basicity
g
1.4 0.7–1.6
rotatable bonds 6.1
a
10-90
th
percentile range;
b
alog P;
c
Elog P – mean of three prediction methods;
d
Sum of N-H and O-H;
e
Abraham A;
f
Sum of N and O atoms;
g
Abra-
ham B
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target site. The discussion above regarding
physical properties of chemicals generally
addresses the distribution, mobility, and
binding of a chemical within a biological
system. Yet specific physical requirements
for cuticular penetration into an insect are
not well understood nor well modelled.
The situation is further complicated as a
number of so-called ‘residual’ insecticides
are not actually active through cuticular
penetration but rather through ingestion,
a route not appropriate for adult mosqui-
to control via either IRS or ITN. The cu-
ticular structure is quite complex, with a
waxy lipophilic exterior transitioning to a
polar interior. The waxy layer is the critical
barrier to chemical penetration and, as an
apparent consequence, polar insecticides
such as the neonicotinoids (e.g. imidaclo-
prid, log P = 0.57
[26]
) are rarely effective as
contact treatments. In contrast, the highly
lipophilic pyrethroids (permethrin, log P =
6.1
[26]
), which readily partition into the cu-
ticular wax, are potent topical insecticides.
Beyond this rather generic requirement for
lipophilicity, it is difficult to provide fur-
ther guidance regarding properties associ-
ated with cuticular penetration.
Finally, it is informative for this discus-
sion of bioavailability predictors to com-
pare the physical property analyses and
guidelines described above with the actual
property values of the WHOPES recom-
mended insecticides for IRS
[6]
and ITN
[8]
(Table 2, Table 4).
[26]
This dataset is limited
to only 13 compounds, and dominated by
pyrethroids, yet it is clear from this com-
parison that the physical properties (both
mean and range) of the WHOPES insecti-
cides fall squarely within the guidelines of
the predictors.
Recommended Guidelines
for Screening Candidates for
Discovery of IRS / ITN Insecticides
The ‘bioavailability predictors’ de-
scribed above have proven useful as pri-
mary filtering tools for potential screening
sets in pesticide discovery and, thus, we
have adapted these to a set of recommenda-
tions for vector-control insecticide discov-
ery (Table 5). It is important to emphasise
that these guidelines are intended solely
for discovery of leads, and not products,
from sets of chemical screening inputs.
That there should be a preferred molec-
ularweight range is interesting. Insecticides
with higher molecular weights than those
proposed in the guidelines are known (e.g.
certain pyrethroids, spinosyns, diamides),
but, as said, these guidelines are intended
for selection ofmaterials as potential leads,
not products. Oprea at AstraZeneca has in-
troduced the concept of ‘lead-like’ space
and its use as an opportunity predictor in
drug discovery.
[27,28]
A total of 96 pharma-
ceutical lead-product couplets were exam-
ined to determine the effect on molecular
properties during the optimisation process.
The analysis showed that, on average, the
molecular weight increased by 79 Da dur-
ing optimisation of a lead to a product (mo-
lecular weight increases as large as 200 Da
were noted), and, even more dramatically,
optimisation resulted in a mean increase in
Table 3. Probability-based (‘drug-like’) bioavailability predictors
Lipinski
[21]
Tice
[22]
(insecticides) Briggs – Rules of 3
[25]
Clarke- Delaney
[24]
molecular weight <500 >150–<500 300 ± 100 200–400
log P or alog P <5 ≥0–≤6.5 3 ± 2
≤4
H-bond donors
a
<5 <2 <3
≤2
H-bond acceptors
b
<10 ≥1–8
rotatable bonds ≤12
melting point <200
o
C <200
o
C
∆ log P
<3
≤2
log water solubility
2 ± 1
pKa
7 ± 2
a
Sum of N-H and O-H;
b
Sum of N and O atoms
Table 4. WHOPES recommended insecticides for malaria vector control
[6,8]
(MW and log P values from The Pesticide Manual
[26]
)
Insecticide Use Chemical Class MW log P
H-bond
acceptors
H-bond
donors
DDT IRS organochlorine 354.5 6.2 0 0
bendiocarb IRS carbamate 223.2 1.72 5 1
bifenthrin IRS pyrethroid 422.9 >6 2 0
cyfluthrin IRS / ITN pyrethroid 434.3 6 3 0
alpha-cypermethrin IRS / ITN pyrethroid 416.3 6.94 3 0
deltamethrin IRS / ITN pyrethroid 505.2 4.6 3 0
etofenprox IRS / ITN pyrethroid 376.5 6.9 3 0
fenitrothion IRS organophosphate 277.2 3.43 5 0
lambda-cyhalothrin IRS / ITN pyrethroid 449.9 7 3 0
malathion IRS organophosphate 330.4 2.75 6 0
permethrin ITN pyrethroid 391.3 6.1 3 0
pirimiphos-methyl IRS organophosphate 305.3 4.2 6 0
propoxur IRS carbamate 209.2 1.56 4 1
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Other Potential Screening
Candidate Filters
In addition to physical property fil-
ters, additional strategies can be used to
enhance the quality of a potential screen-
ing set for a vector-control insecticide.
Foremost among these is prior evidence of
activity in an analogous in vivo assay and,
specifically, activity against insect species
(e.g. dipteran). In addition, as discussed
above, hits from a biochemically-relevant
high-throughput in vitro assay would be
good candidates for the primary in vivo
assay.
Primary Assay (Identification of
Actives, Fig. 3)
The primary assay is intended to give
the test chemical the best chance of show-
ing activity (i.e.maximal contact, minimal
metabolic potential) against a single insect
species. The exact nature of the assay will
depend largely on the number of com-
pounds available for testing. The two most
typical options are a mosquito larval assay
or a simplified contact adult mosquito as-
say (see Secondary Assay below).
Mosquito larval assay features:
· Aedes aegypti larvae contained in a mi-
crotiter plate and bathed in an aqueous
solution of the screening candidate
· Chemical added as a concentrated solu-
tion in an organic solvent (acetone or
DMSO) and diluted with water to the
desired concentration (5–30 ppm)
· Single dose of the chemical, dose cho-
sen to ensure an acceptably small num-
ber of false negatives
· Appropriate doses of relevant stand-
ards (positive controls – minimally per-
methrin and bendiocarb) and negative
controls must be included
· Graded as pass/fail, based on num-
ber of dead or affected insects in each
replicate as compared to controls and
standards
· Sufficient number of insects per treat-
ment to ensure statistically reliable re-
sults (minimum 5, preferably 10)
· It is important to confirm positive
results by repeat tests with the com-
pounds concerned, usually with 2–3
replicates
tirely clear but the undesirable nature of
basic amines within insecticides probably
reflects both a bioavailability requirement,
which dictates that materials must not be
ionised at physiological and environmental
pH, and the high potential for amines to be
metabolically oxidised. This is an impor-
tant attribute to consider when purchasing/
assembling insecticide screening libraries,
as commercial offerings have been largely
designed to meet the needs of the pharma-
ceutical industry. Thus one can expect such
libraries will contain a disproportionate
number of amine-containing compounds
that are unacceptable for insecticide dis-
covery purposes.
Finally, while the recommended guide-
lines may initially appear to be rather re-
strictive and limiting, we would point out
that there are >35 million commercial
chemicals available
[29]
for screening and
a near incalculable number of additional
materials which could be prepared from
typical organic elements (C, H, N, O, P,
S, halogens) via either conventional or
combinatorial organic synthesis. Rather,
we view the guidelines as liberating, as
they allow the insecticide prospector to
focus on the region of chemical space that
offers the greatest opportunity to uncover
novel bioactivity. Probably some leads will
be missed by using these property filters
to design screening sets; but with finite
resources, leads always will be missed re-
gardless of the screening approach.
log P of 1.25 units (range = +0.5-4). His
rationale for such significant differences
was that the typical goal of optimisation
is to increase potency; this usually means
addition of binding recognition elements
thus increasing complexity, which in turn
increases both molecular weight and lipo-
philicity. Furthermore, he points out that
if one starts with leads that are already
towards the upper limit of the ‘drug-like’
properties (Lipinski, Tice, etc.) then the
optimisation process may result in mate-
rials whose log P and molecular weight
fall outside of the drug-like range. Finally,
from a pragmatic standpoint, molecular
weight might be considered to be a very
crude indicator of molecular complex-
ity and thus, indirectly, the ultimate cost
of the active ingredient, which should be
minimised for a vector-control insecticide.
The remaining guidelines reflect the
lipophilic requirement to enable insect cu-
ticular penetration, the need to purge the
screening set of undesirable functionalities
(metals, reactive chemicals), and a desire
to enrich the screening pool with meta-
bolically robust materials. Most of these
properties can be calculated from the mo-
lecular structure, but others, such as chem-
ical reactivity, are more difficult to define
and eliminate. In these instances, it may
be more practical to purge such materials
from the ‘active’ list following the primary
assay.
The exclusion of basic amines from the
screening pool is also worthy of further
discussion. Of the 243 commercial insecti-
cides examined by Tice
[22]
only 2.8% were
found to contain an aromatic amine and
none contained a 1
o
, 2
o
, 3
o
aliphatic amine
or a 3
o
aromatic amine. This is in marked
contrast to the Lipinski
[21]
set where >60%
of the 6454 pharmaceuticals contained a
1
o
, 2
o
, or 3
o
aliphatic or aromatic amine.
The reason for this striking difference in
functional group distribution is not en-
Table 5. Guidelines for selection of screening candidates for insecticide discovery
Property Guideline
molecular weight 200–400
alog P 3–6
H-bond donors ≤1
H-bond acceptors ≤8
pka 7 ± 2
undesirable elements no metals or boron
reactive functionalities eliminate alkylating and arylating agents, aldehydes
basic moieties eliminate 1
o
, 2
o
or 3
o
aliphatic or aromatic amines
acidic moieties eliminate carboxylic acids, electron deficient phenols
ionized molecules eliminate salts
metabolizable
functionalities
minimize alcohols, phenols, electron-rich aromatics
Fig. 3. Primary screen of medium-large sets of chemicals to uncover in vivo insect ‘actives’.
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collaboration with an external partner,
e.g. the LITE (Liverpool Insect Testing
Establishment) at the Liverpool School of
Tropical Medicine
[30]
or the MR4 program
(Malaria Research and Reference Reagent
Resource Center).
[31]
Assay Format
· Contact from surface as described
above
· Multiple susceptible mosquito species
(must include Anopheles gambiae and
Anopheles arabiensis)
· Multiple resistantmosquito strains (e.g.
KisumuRDL,Akron, Fumoz, Cayman,
Tiassale); this selection will be based
on the latest judgements regarding im-
portance of these strains to field resist-
ance mechanisms, and advice on this
should be obtained from the IVCC
· Appropriate doses of relevant stand-
ards (positive controls – minimally per-
methrin and bendiocarb) and negative
controls must be included
· Sufficient number of replicates to en-
sure statistically significant results
(minimum 3)
· Dose responses must be generated
· End-point for each chemical reported
as a breakpoint (LD
90
) and referenced
to that of the standards and the controls
A thorough analysis of the attributes of
the chemistry Hit class should be initiated
at this stage to fully characterise potential
for advancement to Lead status.
Chemical Properties
· Chemical integrity; purity of sample;
isomers and isomeric ratios; isomer in-
terconversions
· Assessment of potential intellectual
property position; ability to obtain sub-
stance and/or use patents for members
of the class
· Physical property measurements (log
P, aqueous and organic solubility)
· Chemical stability (hydrolytic, photol-
ytic) evaluated using analytical tools
(HPLC, LC/MS) instead of bioassay
Chemistry Breadth
· Evaluated through procurement (pur-
chase or synthesis) and bioassay of ad-
ditional analogues of Hit class
The intent is to provide a clear indica-
tion that development of SAR is feasible
(i.e. there are multiple examples of poten-
cy within the series) and to provide initial
guidance for possible downstream lead op-
timisation. This should not be construed as
an effort to optimise the series at this stage.
Synthetic Accessibility:
· Do viable routes exist to generate req-
uisite quantities of multiple, diverse
analogues in an optimisation program?
· Any expensive reagents or starting ma-
· At conclusion of assay the number of
dead/affected/live insects counted to
determine% lethality for each replicate
· Appropriate doses of relevant stand-
ards (positive controls – minimally per-
methrin and bendiocarb) and negative
controls must be included
· Dose responses must be generated at
this phase
· End-point for each chemical reported
as an LD
90
and referenced to that of the
standards and the controls
The approximate speed of action for
each confirmed adult active should be de-
termined by varying contact time with the
chemical and/or by evaluation at various
time points post contact (30 sec.–30 min).
Non-lethal affects and symptomology
should be noted – these could provide im-
portant information regarding knockdown
or repellent potential, possible clues to the
mechanism of action (MOA) of the chem-
istry, or may suggest novel control mech-
anisms.
Note that activity via ingestion or injec-
tion of the mosquito is not relevant to the
intended uses (ITN, IRS). However, such
information may be of value to a particular
research program as a means to understand
the biokinetic properties of a particular
chemical or class of chemicals.
Tertiary Assays (Lead Identification,
Fig. 5)
Spectrum of Mosquito Control, and
Activity Against Resistant Strains
A primary goal at this stage is to de-
termine the activity of the chemical class
against a broader set of mosquito species/
strains. The selection may include rep-
resentative susceptible Aedes and Culex
species but must include Anopheles gam-
biae and Anopheles arabiensis. The ma-
terials must also be tested against a panel
of available and well-characterised insec-
ticide resistant mosquito strains chosen
to represent the range of critical field re-
sistance mechanisms (kdr, rdl, metabo-
lism...). Assays against the resistant strains
may need to be accomplished through
The mosquito larval assay is a useful
tool to sift through large screening sets,
but a significant number of false positives
can be anticipated. There are multiple po-
tential mechanisms for lethality in such a
low barrier larval assay, many of which are
not relevant to adult mosquitoes and others
are inconsistent with the requisite topical
activity. For these reasons it is essential to
regard the larval assay as a simple prog-
nosticative tool and avoid the temptation
to optimise activity against larvae.
Secondary Assay (Hit Identification,
Fig. 4)
The primary purpose of the secondary
assay is to uncover relevant lethal activity
against a susceptible strain of female adult
mosquitoes. The initial assay may be run
by topically dosing each individual insect
with a solution of the chemical. However,
at this stage, an assessment must be made
of the lethality resulting fromdirect pick-up
(tarsal contact) of the chemical by the mos-
quito from an inert surface (glass, plastic,
glased tile). Activity in topical tests does
not necessarily correlate with that in direct
‘pick-up’ contact tests; the latter is more
relevant to the use pattern in practice (i.e.
tarsal contact with ITN or IRS surfaces).
Contact mosquito assay features:
· Susceptible Aedes strain acceptable,
but Anopheles species preferred
· Assay conducted in a confined space
(bottle, petri dish, tube, WHO cone
etc.), to maximise contact of the insects
with the treated surface
· A portion or preferably all of the sur-
face is coated with a solution of the
chemical and dried to a film
· Female adult mosquitoes added to con-
tainer and remain in contact with the
chemical for a defined period of time
– 30 minutes preferred
· The insects are then monitored for the
duration of the assay (minimum 24,
preferably 72 h)
· Sufficient number of replicates to en-
sure statistically significant results
(minimum 3)
Fig. 4. Characterisation of ‘active’ chemistries for advancement to ‘Hit’ status.
Fig. 5. Characterisation of ‘Hit’ classes of chemistry for advancement to ‘Lead’ status or termina-
tion.
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projected use rate, will determine a cost/
treatment. Software is available to assist
in such analyses; potential development
collaborators will need to have expertise
in these studies.
Biological assays, beyond the routine
contact assays needed to support the SAR
development, should be directed towards
demonstration of potential efficacy under a
‘real world’ scenario. As before, all assays
must generate dose-responses and include
appropriate product standards (WHOPES
and commercial). Such studies will re-
quire the development of well-defined,
commercially-viable formulations for IRS
and/or ITN. For ITN uses, the ability to in-
corporate a lead chemical into and onto a
polymeric matrix should also be assessed.
Demonstration of residual activity will
be required for IRS and/or ITN applica-
tions using methods described in WHO
guidelines
[32]
e.g. ‘Cone’ or, preferably,
‘Cylinder’ tests and optionally, ‘Tunnel’
tests for bioassay. Residual effect, suitable
for use in ITN, is assessed through simulat-
ed bed-net washings using both bioassay of
nets, and chemical analyses of washings.
IRS residual stability is determined by
treatments of a number of representative
surface types (mud, concrete, plywood,
thatch, bamboo, etc.)
[32]
with the formu-
lated chemical and assessed again through
both biological and chemical endpoints.
WHOPES provides well-defined testing
protocols for evaluation of insecticide per-
sistence on nets and on substrates typical
of those found in the walls and roofs of
village residences.
[32–34]
Toxicological studies should continue
to focus on probe, single-dose acute oral
rodent assays to help guide the optimisa-
tion program and to characterise promising
candidates. Initial planning should com-
mence (logistics, resource commitments)
to conduct the early-stage toxicological
studies (acute oral, acute dermal, muta-
genicity, carcinogenicity, reproductive tox-
icology, 90-day chronic) needed to support
a registration package for a development
candidate. Probe eco-toxicological studies
should be initiated against aquatic organ-
isms (fish, algae, Daphnia).
leaders consult with members of IVCC for
guidance regarding the assays that are re-
quired, sources of expertise, and potential
collaborative strategy and resources.
The goal of this stage will be optimi-
sation of the lead chemistry against the
TPP attributes. Chemical synthesis and
SAR development will be a primary ac-
tivity and would ideally be supported with
appropriate binding assays, biokinetic
studies, and computational chemistry ef-
forts. Obviously the discussion regarding
preferred physical property values and
structural features for screening compound
selection is still of importance during the
optimisation process. The optimisation
will undoubtedly include many trade-offs
and in many cases potency will not be the
sole or most important driver for selection
or advancement of a development candi-
date. It is thus critical to define and focus
on the limiting attributes of the lead class
and design synthetic analogues and appro-
priate assays (biological or chemical), and
for toxicity to non-target organisms (in-
cluding man) accordingly. For example, in
some series the ability to design and pre-
pare analogues that block insect metabo-
lism may result in higher levels of potency
and/or a greater degree of control of meta-
bolically-resistant mosquitoes. In contrast,
in other areas of chemistry, the addition of
a metabolically-labile functionality might
result in selective mammalian detoxifica-
tion and an improved safety profile.
The synthetic program should also be
designed towards ensuring that freedom to
operate (FTO) exists for the development
candidate. Patent applications (if relevant)
should be filed early in this stage and ena-
bling materials prepared and tested to sup-
port the claims of the application. At the
end of this phase there should be clear ev-
idence that FTO will be attained. The dis-
covery program will undoubtedly neces-
sitate synthesis of quantities of materials
for formulation development, toxicologi-
cal studies, and specialised and intensive
biological testing, including field trials.
The chemical synthesis program should
begin to suggest potential manufacturing
routes for ultimate commercial prepara-
tion. These should be subjected to ‘cost
of goods’ analyses which, coupled with a
terials; complex and difficult to sepa-
rate reaction mixtures/isomers?
Mammalian Toxicology
· Probe with a single dose (≥50 mg/kg)
acute oral assay in either mice or rats
(typically three animals are sufficient
for an initial test)
· Assessment of mutagenicity potential
of Hit class (Ames test)
Broad-Spectrum Insect Control
· Agricultural pests – representative
chewing (Lepidoptera) and sucking
(aphids, whiteflies, hoppers) insects
· Public health pests – houseflies and
cockroaches
· Animal health pests – flies, ticks
The scope of the analysis should be
sufficient to give an indication of the com-
mercial potential for insect control beyond
mosquitoes; testing should be done in a
way (presentation, rates) that allows com-
parison of activity with relevant commer-
cial standards for these pests. A broader
spectrum, which raises commercial attrac-
tiveness and the potential for development
cost-sharing, is valuable to the IVCC in
order to stimulate the interest of possible
development partners.
Biochemistry
· Directed toward determination of
MOA of Hit class
· Corroborate and support bioassay re-
sults with resistant mosquito strains
· Include assays to identify compounds
with unacceptable/potentially prob-
lematic MOA’s:
o non-specific or reactive chemistry
o non-selective AChE inhibitors
o uncouplers of oxidative phospho-
rylation
Probe Formulations
· Simple formulations, e.g. EC (emul-
sifiable concentrate) or WP (wettable
powder), prepared and evaluated via
bioassay
Molecular properties analyses may
provide important clues regarding effec-
tive formulation types or point to potential
bioavailability issues (e.g. solubility, crys-
tallinity, polarity) within the class.
Development Candidate Selection
Phase (Lead Optimisation, Fig. 6)
Many of the activities and assays asso-
ciated with this stage of the discovery ef-
fort will be specific to a particular class of
chemistry. The discussion below is intend-
ed to provide general guidance of the types
of efforts and information needed in this
phase. At this stage, and preferably earli-
er, it is essential that the research project
Fig. 6. Lead Optimisation, and selection of Development Candidate(s).
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cides for use in IRS or ITN if they have
been evaluated through the WHOPES
Phase system described above. Note that
the WHOPES guidelines are intended
to evaluate the efficacy of the products
against “a fully susceptible Anopheles vec-
tor species” and, thus, do not directly ad-
dress the efficacy of ITN products against
resistant mosquitoes. For this purpose,
the WHO Vector Control Advisory Group
(VCAG) has published separate guidelines
for evaluation of new ITN products against
pyrethroid resistant mosquitoes.
[35]
It should be noted that a new process
for evaluation and adoption of novel vec-
tor control products by WHO is currently
under development. Under this procedure,
responsibility for such evaluation will be
transferred from WHOPES to a vector
control products WHO Prequalification
Team.
[36]
The Prequalification process,
which has not yet been fully defined, will
be implemented in 2017.
[37]
It should be clear that the discovery to
development process for a new vector con-
trol insecticide is multifaceted, time con-
suming and expensive. The complexity of
the overall process demands the collective
expertise of individuals from a number of
disciplines including chemistry (synthesis,
computational, process), biology (ento-
mology, field biology, genetics), biochem-
istry, toxicology, patent law, environmental
science, and formulation science, to name
a few. Only the largest industrial organi-
sations will have both the level of expe-
rience and the breadth of expertise neces-
sary to successfully navigate the complete
path from identification of the conceptual
target product profile through delivery of
an effective vector control agent to the
consumer. It is therefore imperative that
the early-stage discovery scientist make
a clear and honest assessment of both the
on a variety of substrates. These activities
are similar to those described under the
‘Development Candidate Selection Phase’
section above.
The second and third stages (Phase II
and III)
[32,33]
of the WHOPES scheme ad-
dress the issues of translation of laboratory
results into real world situations; these tri-
als must be conducted in a regionwhere the
malaria vector is endemic. In each phase,
the insecticide is either incorporated into,
or coated onto, bed nets or sprayed onto
the walls of human-occupied residences;
the residences are accessible to free-fly-
ing native mosquito populations. Phase II
field trials are small-scale in nature and are
conducted in individual, experimental huts
under very carefully controlled conditions;
the intent is to validate the laboratory-de-
termined efficacy and residuality of the
treatment and to establish the appropriate
dose rate. Efficacy, at this stage, is eval-
uated using the cone bioassay, employing
susceptible, laboratory-reared mosquitoes
of the local vector species. Phase III field
trials are much larger in scope, are directed
at determining the effect of the treatment
at the whole community level rather than
individual residences, and the experimen-
tal variables of the trial are, of necessity,
much less well-controlled than those of the
Phase II trials. The purpose, as in Phase II,
is primarily to confirm efficacy and residu-
ality of the product but this phase will also
assess the acceptance and ease of use of
the net or formulation by the occupants of
the community and the applicators as well
as document any perceived side effects to
the community. The design of the Phase II
and Phase III studies is critical, in order
to provide statistically significant proof of
the efficacy and duration of activity of the
insecticide.
WHO will only recommend insecti-
Discussion
In this report we have described a
screening cascade that can be used for
sorting and evaluation of sets of chemi-
cals in order to select a viable candidate
for further development for use as a ma-
laria vector control agent. Identification
of such a candidate represents only the
first step in the rigorous and complex de-
velopment process leading to successful
registration, commercialisation and pub-
lic acceptance of an insecticide for use in
vector control. Many of these development
activities are typical of any new pesticide
active ingredient and will include such de-
tails as the selection and characterisation
of final formulation(s), full toxicological
and eco-toxicological testing, intellectu-
al property protection, identification of a
cost-acceptable process route along with
logistics for manufacture of the active in-
gredient, a final risk assessment, assembly
of a data package for submission to reg-
ulatory authorities, and preparation of a
market access plan (Fig. 7).
An essential step in the development
process for a malaria vector control agent
is the evaluation of the formulated active
ingredient under field conditions. For this
purpose, WHOPES describes a detailed
three-phased program (Fig. 8) for evalu-
ation of IRS or ITN targeted insecticides
using defined and standardised testing
procedures.
[32,33]
In the initial stage of this
WHOPES protocol, Phase I, the biological
activity of the development candidate is
fully characterised under laboratory con-
ditions. The candidate is profiled against
mosquitoes that are representative of the
region where the product is likely to be em-
ployed and the efficacy and residuality of
the formulated active ingredient, and wash
resistance in the case of ITN, determined
Fig. 7. Discovery to Registration Scheme.
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2020 and 2024. The new active ingredients
for vector control will need to be managed
by using mixtures of chemistries and/or
well-designed rotation plans to optimise
their field performance and to delay the
evolution of resistant mosquito strains.
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strengths and the limitations of their organ-
isations’ research and development capa-
bilities as it relates to the overall goal of
delivery of a novel vector control insecti-
cide. This will then allow the discovery sci-
entist to identify missing capabilities and
seek appropriate collaborator(s) who have
access to the level and types of expertise
needed to ensure timely progress along the
discovery to development pathway. The
IVCC can assist the discovery scientist in
conducting the expertise gap analysis as
well as in the identification of appropriate
discovery and development partners.
In conclusion, the current lack of a
sufficient number of unique classes of in-
secticides for use in IRS and ITN, i.e. ma-
terials which function by a diversity of bio-
chemical mechanisms, represents a critical
threat to the malaria eradication goal. The
Innovative Vector Control Consortium
(IVCC), funded by donors including the
UK and US governments and the Bill and
Melinda Gates Foundation, is working
with a broad range of partners around the
world to develop a new generation of in-
secticide treated bed nets, indoor residual
sprays and tools to manage outdoor disease
transmission for use against malaria in de-
veloping countries. The IVCC NewActive
Ingredient TPP describes the essential at-
tributes required for such insecticides and
the TPP, in turn, serves as the basis for a
discovery cascade that can be used to se-
lect a candidate for further development
for use as a malaria vector control agent.
Discovery scientists are strongly encour-
aged to maintain a focus on the TPP attrib-
utes and use these as a continuous guide in
the decision making and compound selec-
tion processes.
At the time of going to press, three
IVCC-funded novel public health insecti-
cide projects with modes of action that are
new to public health are in the pre-develop-
ment stage, with launch expected between
Fig. 8. Phases of the WHOPES evaluation protocol for new insecticides for malaria vector control.
